CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the launch of a new web-based platform, RegistryNXT!SM, to support the International Collaborative Gaucher Group (ICGG) Gaucher Registry. The first and largest database of its kind in the world, the global ICGG Gaucher Registry was built to promote the understanding of Gaucher and to track the outcomes of treatments worldwide. Now in its 20th year, nearly 30 published papers on Gaucher disease have resulted from the wealth of observational data in the registry.
